Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C

Jennifer R Havens, Takako Schaninger, Hannah Fraser, Michelle Lofwall, Michele Staton, April M Young, Ardis Hoven, Sharon L Walsh, Peter Vickerman, Jennifer R Havens, Takako Schaninger, Hannah Fraser, Michelle Lofwall, Michele Staton, April M Young, Ardis Hoven, Sharon L Walsh, Peter Vickerman

Abstract

Objectives: The overall goal of the Kentucky Viral Hepatitis Treatment Study (KeY Treat) is to eliminate hepatitis C transmission from a county in Appalachian Kentucky by removing the barriers to accessing hepatitis C virus (HCV) treatment.

Methods/analysis: KeY Treat is a phase IV, open-label, single-arm clinical trial of sofosbuvir/velpatasvir (SOF/VEL) for the treatment of viraemic HCV infections. Those eligible for KeY Treat are at least 18 years of age, viraemic and are residents of the target county. Pregnant women are not eligible. Rapid HCV RNA screening is used to determine eligibility, and those with a quantifiable viral load (VL) consenting to participate initiate SOF/VEL on the same day. All pharmacologic treatment and related medical care is provided free of charge using a non-specialist provider model. Follow-up visits occur at 2, 6 and 12 weeks during treatment to assess medication adherence (measured via VL and self-report), side effects and engagement in risk behaviours. Post-treatment visits occur at 12 weeks (sustained virologic response (SVR12) visit), 6 months and 12 months post-treatment completion to assess re-infection. A control county has also been identified, and prevalence and incidence of chronic HCV infections will be compared with the target community longitudinally. The primary outcome to assess elimination is SVR12. However, several outcomes will be measured to assess the effectiveness of removing the barriers to HCV treatment, including treatment entry, completion and re-infection. Analyses will be conducted via a generalised linear model framework that can incorporate flexible covariate adjustment and multiple outcome types with a compatible link function. Mathematical modelling will be completed assessing the impact and cost-effectiveness of the intervention.

Ethics and dissemination: KeY Treat has been approved by the Institutional Review Board at the University of Kentucky. Results from KeY Treat will be presented at conferences and published in peer-reviewed journals.

Trial registration number: NCT03949764.

Keywords: epidemiology; hepatology; public health.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Davis GL, Albright JE, Cook SF, et al. . Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331–8. 10.1053/jlts.2003.50073
    1. Rosen HR. Clinical practice. chronic hepatitis C infection. N Engl J Med 2011;364:2429–38. 10.1056/NEJMcp1006613
    1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553–62. 10.1038/nrgastro.2013.107
    1. Applegate TL, Fajardo E, Sacks JA. Hepatitis C virus diagnosis and the Holy Grail. Infect Dis Clin North Am 2018;32:425–45. 10.1016/j.idc.2018.02.010
    1. Spengler U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther 2018;183:118–26. 10.1016/j.pharmthera.2017.10.009
    1. Ascione A, De Luca M, Tartaglione MT, et al. . Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010;138:116–22. 10.1053/j.gastro.2009.10.005
    1. Cornberg M, Wedemeyer H, Manns MP. Treatment of chronic hepatitis C with pegylated interferon and ribavirin. Curr Gastroenterol Rep 2002;4:23–30. 10.1007/s11894-002-0034-y
    1. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. . Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017;166:637–48. 10.7326/M16-2575
    1. Baumert TF, Berg T, Lim JK, et al. . Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology 2019;156:431–45. 10.1053/j.gastro.2018.10.024
    1. Jones CR, Flower BF, Barber E, et al. . Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res 2019;4:132. 10.12688/wellcomeopenres.15411.1
    1. Marcellin F, Roux P, Protopopescu C, et al. . Patient-Reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol 2017;11:259–68. 10.1080/17474124.2017.1285227
    1. Latham NH, Doyle JS, Palmer AY, et al. . Staying hepatitis C negative: a systematic review and meta-analysis of cure and reinfection in people who inject drugs. Liver Int 2019;39:2244–60. 10.1111/liv.14152
    1. Day E, Hellard M, Treloar C, et al. . Hepatitis C elimination among people who inject drugs: challenges and recommendations for action within a health systems framework. Liver Int 2019;39:20–30. 10.1111/liv.13949
    1. Grebely J, Dore GJ, Morin S, et al. . Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? J Int AIDS Soc 2017;20:22146. 10.7448/IAS.20.1.22146
    1. Hajarizadeh B, Grebely J, Martinello M, et al. . Hepatitis C treatment as prevention: evidence, feasibility, and challenges. Lancet Gastroenterol Hepatol 2016;1:317–27. 10.1016/S2468-1253(16)30075-9
    1. Martin NK, Vickerman P, Grebely J, et al. . Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013;58:1598–609. 10.1002/hep.26431
    1. Martin NK, Vickerman P, Dore GJ, et al. . Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol 2016;65:17–25. 10.1016/j.jhep.2016.02.007
    1. Barbosa C, Fraser H, Hoerger TJ, et al. . Cost-Effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. Addiction 2019;114:2267–78. 10.1111/add.14731
    1. Morris MD, Mirzazadeh A, Evans JL, et al. . Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: low number treated. Drug Alcohol Depend 2019;198:133–5. 10.1016/j.drugalcdep.2019.02.008
    1. Wolfe D, Luhmann N, Harris M, et al. . Human rights and access to hepatitis C treatment for people who inject drugs. Int J Drug Policy 2015;26:1072–80. 10.1016/j.drugpo.2015.05.007
    1. Litwin AH, Drolet M, Nwankwo C, et al. . Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C-SCOPE study. J Viral Hepat 2019;26:1094–104. 10.1111/jvh.13119
    1. Pedlar A, Sandhu Prabjot (Jodie), Sandhu PJ. Promoting treatment for hepatitis C in people who inject drugs: a review of the barriers and opportunities. J Am Assoc Nurse Pract 2020;32:563–8. 10.1097/JXX.0000000000000269
    1. Trickey A, Fraser H, Lim AG, et al. . The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol 2019;4:435–44. 10.1016/S2468-1253(19)30085-8
    1. Fraser H, Zibbell J, Hoerger T, et al. . Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic. Addiction 2018;113:173–82. 10.1111/add.13948
    1. Platt L, Minozzi S, Reed J, et al. . Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a cochrane review and meta-analysis. Addiction 2018;113:545–63. 10.1111/add.14012
    1. Fraser H, Vellozzi C, Hoerger TJ, et al. . Scaling up hepatitis C prevention and treatment interventions for achieving elimination in the United States: a rural and urban comparison. Am J Epidemiol 2019;188:1539–51. 10.1093/aje/kwz097
    1. Zibbell JE, Iqbal K, Patel RC, et al. . Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep 2015;64:453–8.
    1. Rosenberg ES, Rosenthal EM, Hall EW, et al. . Prevalence of hepatitis C virus infection in US states and the district of Columbia, 2013 to 2016. JAMA Netw Open 2018;1:e186371. 10.1001/jamanetworkopen.2018.6371
    1. Havens JR, Lofwall MR, Frost SDW, et al. . Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health 2013;103:e44–52. 10.2105/AJPH.2012.300874
    1. Schalkoff CA, Lancaster KE, Gaynes BN, et al. . The opioid and related drug epidemics in rural Appalachia: a systematic review of populations affected, risk factors, and infectious diseases. Subst Abus 2020;41:35–69. 10.1080/08897077.2019.1635555
    1. Valdiserri R, Khalsa J, Dan C, et al. . Confronting the emerging epidemic of HCV infection among young injection drug users. Am J Public Health 2014;104:816–21. 10.2105/AJPH.2013.301812
    1. Zibbell JE, Asher AK, Patel RC, et al. . Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health 2018;108:175–81. 10.2105/AJPH.2017.304132
    1. Perlman DC, Jordan AE. The Syndemic of opioid misuse, overdose, HCV, and HIV: Structural-Level causes and interventions. Curr HIV/AIDS Rep 2018;15:96–112. 10.1007/s11904-018-0390-3
    1. Conrad C, Bradley HM, Broz D, et al. . Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone--Indiana, 2015. MMWR Morb Mortal Wkly Rep 2015;64:443–4.
    1. Peters PJ, Pontones P, Hoover KW, et al. . Hiv infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med 2016;375:229–39. 10.1056/NEJMoa1515195
    1. Ramachandran S, Thai H, Forbi JC, et al. . A large HCV transmission network enabled a fast-growing HIV outbreak in rural Indiana, 2015. EBioMedicine 2018;37:374–81. 10.1016/j.ebiom.2018.10.007
    1. Platt L, Easterbrook P, Gower E, et al. . Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016;16:797–808. 10.1016/S1473-3099(15)00485-5
    1. Van Handel MM, Rose CE, Hallisey EJ, et al. . County-Level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr 2016;73:323–31. 10.1097/QAI.0000000000001098
    1. Bixler D, Corby-Lee G, Proescholdbell S, et al. . Access to syringe services programs - Kentucky, North Carolina, and West Virginia, 2013-2017. MMWR Morb Mortal Wkly Rep 2018;67:529–32. 10.15585/mmwr.mm6718a5
    1. Young AM, Crosby RA, Oser CB, et al. . Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol 2012;84:1376–87. 10.1002/jmv.23252
    1. Stephens DB, Young AM, Havens JR. Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs. Int J Drug Policy 2017;47:86–94. 10.1016/j.drugpo.2017.05.045
    1. Hofmeister MG, Havens JR, Young AM. Silence surrounding hepatitis C status in risk relationships among rural people who use drugs. J Prim Prev 2017;38:481–94. 10.1007/s10935-017-0483-6
    1. Young AM, Jonas AB, Mullins UL, et al. . Network structure and the risk for HIV transmission among rural drug users. AIDS Behav 2013;17:2341–51. 10.1007/s10461-012-0371-2
    1. Strickland JC, Staton M, Leukefeld CG, et al. . Hepatitis C antibody reactivity among high-risk rural women: opportunities for services and treatment in the criminal justice system. Int J Prison Health 2018;14:89–100. 10.1108/IJPH-03-2017-0012
    1. Chhatwal J, Wang X, Ayer T, et al. . Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology 2016;64:1442–50. 10.1002/hep.28571
    1. Rodriguez SD, Vanderford NL, Huang B, et al. . A Social-Ecological review of cancer disparities in Kentucky. South Med J 2018;111:213–9. 10.14423/SMJ.0000000000000794
    1. Herdman M, Gudex C, Lloyd A, et al. . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36. 10.1007/s11136-011-9903-x
    1. Cacciola JS, Alterman AI, McLellan AT, et al. . Initial evidence for the reliability and validity of a "Lite" version of the Addiction Severity Index. Drug Alcohol Depend 2007;87:297–302. 10.1016/j.drugalcdep.2006.09.002
    1. Needle R, Fisher DG, Weatherby N, et al. . Reliability of self-reported HIV risk behaviors of drug users. Psychology of Addictive Behaviors 1995;9:242–50. 10.1037/0893-164X.9.4.242
    1. Demidenko E. Sample size determination for logistic regression revisited. Stat Med 2007;26:3385–97. 10.1002/sim.2771

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner